Enanta doses first patient in Phase 2b/3 trial of RSV drug zelicapavir
ENTA•Enanta Pharmaceuticals dosed the first patient in RESOLVE, a Phase 2b/3 trial of zelicapavir for adults at high risk from RSV. Phase 2b results are expected in 2027, with at least 200 patients; the Phase 3 portion is expected to enroll approximately 660.
1. Trial details
The trial’s primary endpoint is complete resolution of all 13 RSV symptoms, and hospitalization rate is a key secondary endpoint. Eligible outpatients must have had RSV symptoms for no more than three days and be of advanced age or have specified heart or lung conditions. A previous Phase 2 trial showed a one-week reduction in time to complete symptom resolution among similarly high-risk patients, with fewer hospitalizations.
